scholarly journals Controversial Issues in Thromboprophylaxis with Low-Molecular Weight Heparins in Palliative Care

2008 ◽  
Vol 36 (2) ◽  
pp. e3-e4 ◽  
Author(s):  
Davide Tassinari ◽  
Carlotta Santelmo ◽  
Emanuela Scarpi ◽  
Paola Tombesi ◽  
Sergio Sartori
Keyword(s):  
Molecular Weight ◽  
Palliative Care ◽  
Low Molecular Weight ◽  
Controversial Issues ◽  
Low Molecular Weight Heparins

scholarly journals Advisory Board conclusion following the discussion "Controversial issues of low molecular weight heparins use in obstetrics"

2021 ◽  
Vol 15 (4) ◽  
pp. 461-469
Author(s):  
Article Editorial
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight ◽  
Controversial Issues ◽  
Systemic Embolism ◽  
Low Molecular Weight Heparins ◽  
Maternal Complications ◽  
Treatment And Prevention ◽  
Increased Risk ◽  
Low Incidence ◽  
Valve Prostheses

Antithrombotic therapy is often used during pregnancy for the treatment and prevention of venous thromboembolism, systemic embolism in patients with heart valve prostheses, for prevention of foetal loss in patients with antiphospholipid syndrome, placenta-mediated complications. In common, low molecular weight heparins (LMWHs) have largely replaced unfractionated heparin as the anticoagulant. However, in case of placenta-mediated complications it has off-label status. The effectiveness and safety of the LMWHs in pregnant women at an increased risk of placenta-mediated complications is discussed in this review. LMWH is effective, safety, easy to administer and associated with a low incidence of foetal and maternal complications.

A Perspective on Low Molecular Weight Heparins in the Management of Thrombosis

1993 ◽  
Vol 13 (S 01) ◽  
pp. S5-S11 ◽  
Author(s):  
Debra Hoppensteadt ◽  
Jeanine Walenga ◽  
A Ahsan ◽  
O Iqbal ◽  
W Jeske ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Mechanism Of Action ◽  
Manufacturing Process ◽  
Laboratory Tests ◽  
Low Molecular Weight ◽  
Low Molecular Weight Heparins ◽  
Pharmacological Management

SummaryThe introduction of low molecular weight heparins has added a new dimension to the pharmacological management of thrombotic disorders. Because of different chemical and pharmacological characteristics, due to the manufacturing process, each LMWH should be considered as a distinct entitity and only be used for its given indication. A list of commercially available LMWHs is included. The mechanism of action of the LMWHs and their use in various disorders are discussed. Available laboratory tests for monitoring LMWHs are presented and their limitations pointed out.

Sign in / Sign up

Export Citation Format

Share Document